{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"41"}]}],"title":"ECOG PS 0 (last value)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"73"}]}],"title":"ECOG PS 1 (last value)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"ECOG PS 2 (last value)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"description":"ECOG PS measured on 6 point scale to assess participant's performance status. 0=Fully active, able to carry on all pre-disease activities without restriction.\n\n1. Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work.\n2. Ambulatory (\\>50 percent of waking hours), capable of all self-care, unable to carry out any work activities.\n3. Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours.\n4. Completely disabled, cannot carry on any self-care, totally confined to bed or chair.\n5. Dead.","groups":[{"description":"Patients received Afatinib monotherapy 40 mg film-coated tablets orally once daily.","id":"OG000","title":"Afatinib 40 mg"},{"description":"Patients received Pemetrexed 500 mg/m\\^2 lyophilised powder as intravenous infusion after Cisplatin 75 mg/m\\^2 solution for infusion as intravenous infusion on Day 1 of each 21-day treatment course up to 6 cycles.","id":"OG001","title":"Pemetrexed/Cisplatin Chemotherapy"}],"paramType":"NUMBER","populationDescription":"RS. Only patients with baseline and at least one post-baseline assessment were included.","reportingStatus":"POSTED","timeFrame":"Throughout the trial until progression (every 3 weeks), up to 28 months.","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","type":"SECONDARY","unitOfMeasure":"Participants"}